BioSpace

Sanofi Moves Away From mRNA Flu Vaccine as CEO Projects Confidence

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.
Fierce Biotech

Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.

Human trials for Japan-developed Nipah vaccine set to begin in April

A Nipah virus vaccine developed by the University of Tokyo is set to begin Phase 1 human trials in April, offering hope ...

CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines

CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine at the World Government Summit 2026 (WGS 2026) which convened from ...

Prepping for future pandemics: MERS vaccine candidate shows long-lasting immune response

A new study has shown for the first time that an experimental vaccine against Middle East Respiratory Syndrome (MERS) induces ...
pharmaphorum

AMR and vaccines: Can universal coverage avert a post-antibiotic era?

A universal vaccine would work to help combat the development of AMR in several ways. Firstly, it would protect the individual from getting infected. Prevention of primary infection removes the ...
GV Wire

FDA Refuses to Review Moderna Flu Vaccine

Moderna's flu vaccine faces FDA hurdles as the agency rejects its approval due to trial comparison concerns. Learn more here.